Straits Times Index
3,279.37 -13.76 (-0.42%) Nikkei
37,628.48 -831.60 (-2.16%) Hang Seng
17,218.39 +17.12 (+0.10%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,291.61 -2,337.54 (-3.51%) CMC Crypto 200
1,391.35 +8.78 (+0.63%)
REGN Jan 2025 700.000 call
| Previous close | 301.61 |
| Open | 298.50 |
| Bid | 308.50 |
| Ask | 317.00 |
| Strike | 700.00 |
| Expiry date | 2025-01-17 |
| Day's range | 298.50 - 301.82 |
| Contract range | N/A |
| Volume | |
| Open interest | 81 |
ZacksTop Stock Reports for Danaher, Regeneron Pharmaceuticals & Palo Alto Networks
Today's Research Daily features new research reports on 16 major stocks, including Danaher Corporation (DHR), Regeneron Pharmaceuticals, Inc. (REGN) and Palo Alto Networks, Inc. (PANW).
GlobeNewswireRegeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Oral presentation will feature new data for investigational REGN7075, an EGFRxCD28 costimulatory bispecific with the potential to enhance the treatment of certain advanced solid tumors in combination with Libtayo® (cemiplimab-rwlc) 17 presentations to highlight Regeneron's investigational pipeline including checkpoint inhibitors, CD3 bispecifics and CD28 costimulatory bispecifics TARRYTOWN, N.Y., April 24, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ne
- GlobeNewswire
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)
Oral presentations include updated results from clinical study of otoferlin gene therapy DB-OTO demonstrating restoration in children with profound genetic hearing loss Additional presentations cover progress in novel genetic medicine delivery systems and immune response modulation TARRYTOWN, N.Y., April 22, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data across its genetic medicines portfolio will be presented at the American Soc
